Pleomorphic undifferentiated sarcoma
| Classification according to ICD-10 | |
|---|---|
| C49.- | Malignant growth of other connective tissue and other soft tissue |
| ICD-10 online (WHO version 2019) | |
Pleomorphic undifferentiated sarcoma (PUS), formerly known as malignant fibrous histiocytoma (MFH), is the fourth most common malignant neoplasm of connective tissue ( sarcoma ) in adults. The age peak is 50–70 years, men are affected somewhat more often than women.
The most common locations are the limbs ( extremities ) and the space behind the peritoneum ( retroperitoneal space ). Most often the tumor metastasizes to the lungs (over 90%). The tumor appears in the extremities as an initially painless mass . It can also occur after previous irradiation or in the vicinity of foreign bodies (implants, projectiles). A diagnosis is made by the pathologist after a biopsy or surgical removal of the tissue. The name serves as a collecting basket for all sarcomas that do not show any differentiation ( rhabdomyosarcoma , leiomyosarcoma , liposarcoma , angiosarcoma, etc.). With the increasing histopathological possibilities, the number of diagnoses has decreased. The prognosis depends on the size and extent of the tumor; 5-year survival rates of 48–77% have been reported.
Sources and individual references
- ↑ Alphabetical index for the ICD-10-WHO version 2019, volume 3. German Institute for Medical Documentation and Information (DIMDI), Cologne, 2019, p. 373
- ↑ a b INSERM US14-- ALL RIGHTS RESERVED: Orphanet: Undifferentiated pleomorphic sarcoma. Retrieved June 22, 2019 .
- C. Bokemeyer, J. Debus: Malignant fibrous histiocytoma (MFH) of the bone . In: Schmoll, Höffken, Possinger: Compendium of internal oncology . Standards in diagnostics and therapy . Part 1: Epidemiology, tumor biology, cytostatics, principles of tumor therapy, supportive measures . 4th edition. Springer Verlag, Heidelberg 2006, ISBN 3-540-20657-4 , pp. 5265-5269.
